慢性淋巴细胞白血病患者暴露于伊布替尼药物相互作用后的结局
一项基于安大略省≥66岁居民的人群队列研究,纳入642例接受伊布替尼治疗的慢性淋巴细胞白血病患者,评估中/强CYP3A抑制剂或诱导剂合并用药频率及其与总生存的关系。中/强CYP3A抑制剂与感染住院风险升高相关(OR 2.88),但与总生存无关联。
要点
- 642例伊布替尼治疗患者中,70例(10.9%)合并使用CYP3A诱导剂,404例(62.9%)合并使用CYP3A抑制剂。
- 合并使用中/强CYP3A诱导剂或抑制剂与死亡(n=162)无关联。
- 合并使用中/强CYP3A抑制剂与感染住院风险升高相关(OR 2.88,95%CI 1.29-6.43)。
核心结论
- 老年慢性淋巴细胞白血病患者中,合并使用CYP3A调节药物常见;合并用药与总生存无关联,但CYP3A抑制剂与感染住院强烈相关,强调药物警戒的重要性。
研究设计与样本
- 基于安大略省≥66岁居民的人群队列研究,纳入642例因慢性淋巴细胞白血病启动伊布替尼治疗的患者(中位年龄74岁,34.4%女性)。
- 次要分析采用巢式病例对照设计,考察出血或感染住院作为伊布替尼毒性的潜在标志。
主要发现
- 642例伊布替尼使用者中,70例(10.9%)合并使用CYP3A诱导剂,404例(62.9%)合并使用CYP3A抑制剂。
- 主要分析中,死亡(n=162)与合并使用中/强CYP3A诱导剂或抑制剂均无关联。
- 次要分析中,86例(13.4%)因出血住院,287例(44.7%)因感染住院。
- 合并使用中/强CYP3A抑制剂与感染住院风险升高相关(OR 2.88,95%CI 1.29-6.43),但与出血住院无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib is metabolized by cytochrome P450 3A (CYP3A) and poses challenges with drug interactions. We conducted a population-based cohort study of Ontario residents aged ≥66 years who initiated ibrutinib for chronic lymphocytic leukaemia (CLL) to evaluate the frequency of potential drug interactions involving moderate/strong CYP3A inhibitors and inducers and their association with overall survival (OS). Secondary analyses employed a nested case-control design examining hospitalizations for haemorrhage or infection as potential markers of ibrutinib toxicity. Among 642 ibrutinib recipients (median age 74 years, 34.4% female), 70 (10.9%) received a concomitant CYP3A inducer while 404 (62.9%) received a concomitant CYP3A inhibitor. In the primary analysis, we found no association between death (n = 162) and concurrent use of either moderate/strong CYP3A inducers or inhibitors. In secondary analyses, 86 patients (13.4%) were admitted to hospital for bleeding and 287 patients (44.7%) for infection. Receipt of moderate/strong CYP3A inhibitors was associated with an increased odds of hospitalization for infection (odds ratio 2.88, 95% confidence intervals [CI] 1.29-6.43) but not haemorrhage. Among older patients receiving ibrutinib for CLL, concomitant use of CYP3A-modulating drugs is common. We found no association between use of interacting drugs and OS, but CYP3A inhibitors were strongly associated with hospitalization for infection, underscoring the importance of pharmacovigilance.
引用
- Hoang T, Cheung MC, Juurlink DN, et al. Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2025. PMID: 40878718. doi:10.1111/bjh.70131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。